Some cases don't just end with a verdict.
They begin there.

The law does not change all at once. It rarely changes with fanfare. Most of the time it changes the way tectonic plates shift—quietly, slowly, invisibly—until one day the ground gives way and what once seemed unthinkable becomes inevitable.

Connecticut, unexpectedly and decisively, has become one of the places where the future arrived first.

That is what is happening now in the national NEC infant formula litigation.

In Hunte v. Yale New Haven Hospital, New Haven Superior Court Judge Karen Goodrow entered judgment in the sum of $31,962,884.42 on December 12, 2025. Yale sought reconsideration. On January 29, 2026, Judge Goodrow denied Yale's Motion to Reargue and Reconsider. The judgment stands, and Yale has appealed.

This is not merely a “big verdict.” It is a warning shot across the bow of neonatal medicine, hospital administration, and corporate product marketing.

And it may ultimately prove to be a turning point in how NICU feeding decisions are communicated, documented, and legally understood.

The verdict matters not simply because of its magnitude, but because of its doctrinal framing: informed consent and battery, grounded in the most basic proposition of American tort law—patients and parents have the right to know what is being done to their bodies, and to make informed decisions about medical risk.

If that sounds obvious, it is.

But in neonatal intensive care units, where urgency and protocol often govern decision-making, the obvious has been quietly eroded.

THE DISEASE THAT MOVES FASTER THAN CONSENT

For years, necrotizing enterocolitis (NEC) has been described in the language of medicine: prematurity, inflammatory cascades, ischemia, sepsis, intestinal necrosis, emergent surgery, multi-organ failure.

But for families who have lived it, NEC has never been a scientific abstraction.

It is a horror with a timeline.

A baby who is improving.
A baby who is suddenly not.
A child who becomes a surgical emergency in hours.
A rapid collapse.
A fatality.

And a death that feels not merely tragic, but senseless.

That is why NEC litigation has never been simply about product liability.

It is about whether tragedy was inevitable—or whether it was preventable, foreseeable, and concealed behind routine.

THE FOG OF CAUSATION

In every major mass tort in American history, there is a moment when a product long treated as routine becomes suspect. At that moment, the first line of defense is almost always the same:

We don't know.
You can't prove it.
Science is uncertain.
Reasonable experts disagree.

This is a powerful strategy because it is often partly true. Many injuries are multifactorial. Many outcomes cannot be traced to a single variable with mathematical certainty. Medicine rarely speaks in absolutes.

But the law does not require absolutes.

The law requires reasonableness.

And once a risk becomes known enough to debate in journals, to study in meta-analyses, to circulate through a medical specialty as a recognized danger, it becomes difficult—eventually impossible—to argue that it is too speculative to disclose.

That is the turning point the NEC litigation has approached.

Because the litigation is not merely about whether bovine-based fortifiers and formulas can “cause” NEC.

It is about whether they increase the risk of NEC compared to exclusive human milk diets and human-derived fortification.

That distinction matters.

Because in informed consent law, the question is not “is this the only cause?”

The question is whether a reasonable parent would want to know the risk in deciding whether to consent.

That is why the fog matters.

And that is why, increasingly, it is clearing.

THE WAR ON THE LAWYERS

The NEC litigation did not begin with institutional credibility. It began as a challenge to an industry deeply embedded in American neonatal care—backed by marketing infrastructure, professional relationships, and a cultural assumption that “formula is safe because it is everywhere.”

That is the quiet power of ubiquitous products.

They become invisible.

When you challenge something invisible, you are treated as suspect.

In the early phases of this litigation, manufacturers and aligned institutions did not simply argue the merits.

They attacked legitimacy.

They attacked the premise that lawyers should even be permitted to litigate this issue at all.

There were early efforts to sanction, intimidate, and denigrate the attorneys who commenced the NEC effort. The subtext was unmistakable: these cases should not exist, and the lawyers bringing them should be punished for trying.

This is not unusual.

It is the oldest chapter in American mass tort history.

It is what happened in asbestos litigation.

It is what happened in tobacco litigation.

It is what happened in opioid litigation.

The early phase is not about truth.

It is about containment.

Because if the narrative becomes accepted, the litigation becomes inevitable.

THE “HUMAN MILK FORTIFIER” LABEL: A PEER-REVIEWED PAPER THAT READS LIKE A DEPOSITION EXHIBIT

One of the most extraordinary aspects of this litigation is that the very consent problem at the heart of the case is now documented in peer-reviewed medical literature.

A study published in Nutrients titled “Parent and Provider Perspectives on the Imprecise Label of ‘Human Milk Fortifier' in the NICU” surveyed parents and providers about what they believed “HMF” meant.

The findings are striking.

Only 21.9% of providers reported consistently describing the source of HMF to parents. Only 20.6% of parents whose child received HMF reported knowing the source. Parents stated they were “not given information,” and both parents and providers stated that the label “HMF” is misleading.

Even more revealing: only 8.8% of parent respondents interpreted “HMF” as potentially meaning a cow's milk-based product.

This is not merely a legal argument.

It is a clinical documentation of the consent breakdown.

And it becomes even more remarkable when one notes that the authorship includes Yale School of Medicine faculty.

In other words, the institution at the center of the Hunte verdict is connected—through scholarship—to published recognition of the very ambiguity that became central at trial.

This is not simply ironic.

It is historically significant.

Because it demonstrates that the consent problem was not invented by plaintiffs after litigation began.

It was recognized in the medical community.

And it was recognized by Yale-connected researchers.

YALE'S DONOR MILK LETTER: A PUBLIC RECORD THAT CHANGES THE STORY

If one document captures the institutional knowledge and public health awareness that may frame the conversation ,  is Yale's February 26, 2019 letter to the Connecticut General Assembly supporting Medicaid coverage for donor breast milk.

In that letter, Yale clinicians state that NEC occurs in 5–7% of very preterm infants. A third die, and another third suffer long-term complications such as short gut syndrome and neurodevelopmental delay.

They state that studies show a 60% reduction in NEC when infants receive donor human milk instead of formula.

They quantify the impact: in Connecticut, they estimated that statewide donor milk access would prevent 18 NEC cases annually and save six lives.

And they note that the annual cost of Yale's donor milk program was $34,000—well below the $225,000 published cost of one case of NEC.

This letter is not a litigation filing.

It is not advocacy written by plaintiff lawyers.

It is Yale neonatologists pleading for legislative action based on NEC prevention science.

It documents awareness.

It documents foreseeability.

And it documents that donor milk was not speculative—it was understood as a life-saving intervention.

Once that record exists, the question becomes unavoidable:

If the institution recognized donor milk as a powerful NEC prevention tool, why were parents not told that bovine-based fortifiers and formulas carried increased NEC risk relative to exclusive human milk strategies?

This is not a question that can be buried under “protocol.”

WHY THE DUTY DOES NOT END AT THE HOSPITAL DOOR

There is a central thesis in this litigation that deserves more attention than it has received.

If hospitals have a duty to disclose, then manufacturers have a duty to warn.

This is not rhetorical. It is doctrinal.

Hospitals are responsible for informed consent.

Manufacturers are responsible for product safety, design, labeling, and warnings.

And the two duties are not independent. They are interlocking.

A physician cannot fully obtain informed consent if the manufacturer's labeling and marketing fail to communicate material risk or obscure the existence of safer alternatives.

In that sense, informed consent is not merely a bedside doctrine.

It is an ecosystem doctrine.

If the ecosystem is misleading, the consent is corrupted before the clinician ever speaks.

That is why the HMF labeling issue is not semantics.

It is the mechanism by which autonomy is either preserved or destroyed.

And that is why Hunte matters.

Because it is a verdict that treats feeding decisions not as administrative routine, but as medical interventions requiring disclosure.

THE ORIGINAL ALLEGATIONS: WHAT THE NEC CASES LOOKED LIKE BEFORE MDL NARROWING

The federal MDL has, as a practical matter, narrowed the legal causes of action and streamlined theories.

That is part of the nature of MDL architecture.

But early state and federal pleadings—filed before the litigation was “managed”—reveal the broader thesis.

The early Connecticut product liability complaint alleges that Aries' parents did not know Similac Human Milk Fortifier was derived from cow's milk, and did not know it placed their baby at increased risk of NEC and death.

It alleges that Abbott failed to warn parents and providers despite knowing of the increased risk, and alleges that Abbott deceived the public, parents, physicians, and medical staff into believing its products were safe and necessary for premature infants.

It alleges, critically, that Abbott failed to require or recommend that hospitals obtain parental consent before feeding these products to premature infants.

Those allegations go beyond negligence.

They allege a marketing and messaging ecosystem that undermined informed consent itself.

And that is precisely why the NEC litigation is so dangerous to corporate defendants.

Because if the “consent collapse” theory takes hold, it is not just about product defect.

It is about systemic deception.

THE LESSON OF THE EARLY MASS TORTS: THE EARLY CASES ARE NEVER THE END

This is the part of the story that trial lawyers understand instinctively and corporate defendants often refuse to accept until it is too late.

The early cases are never “the end.”

They are the beginning of the end.

In asbestos litigation, the early plaintiffs were treated as outliers. The lawyers were attacked. The science was dismissed. The claim was framed as speculative. For years, denial functioned as strategy.

Until it didn't.

In tobacco litigation, the refrain was “no proof” until the narrative shifted and internal documents surfaced. At that point, the industry's problem was no longer causation.

It was credibility.

In opioid litigation, blame was pushed onto patients and prescribers until the record matured and marketing strategy became impossible to deny.

The pattern is always the same.

The early phase is not about winning.

It is about making plaintiffs lose hope.

Delay as a strategy.
Exhaustion as a strategy.
Discrediting as a strategy.

But if the litigation survives long enough, something inevitable happens.

The science becomes less theoretical.
The story becomes coherent.
The jury psychology changes.
The verdicts begin to speak with a single voice.

The NEC litigation is reaching that phase now.

Connecticut may be remembered as one of the places where that shift became visible.

Because when a court issues a verdict like Hunte, and then refuses to retreat when challenged, it sends a message that echoes far beyond the parties:

This is no longer speculative.
This is no longer fringe.
This is now part of the law.

And once it becomes part of the law, it becomes part of the standard of care.

A CALL TO THE PROFESSION

This litigation is not simply about what happened to infants in the past.

It is about what we choose to do now, knowing what we know.

To neonatologists: the duty of care is not only clinical. It is communicative. Parents cannot meaningfully participate in decision-making if risk is filtered through euphemism, minimized as routine, or concealed behind labels that imply safety.

To hospital administrators: it is not enough to say “we follow protocol.” Protocol is not immunity. Protocol is not consent. And protocol will not protect an institution when medical literature increasingly recognizes that disclosure is required.

To policymakers: access to donor milk and human-derived fortifiers is not a luxury. It is becoming a standard-of-care equity issue. Yale clinicians made that case in 2019, with plain numbers and plain urgency.

And to manufacturers: denial is not a long-term strategy.

It is a countdown.

The NEC litigation is not merely about compensation.

It is about transparency.
It is about informed choice.
It is about whether preventable tragedies remain acceptable simply because they are familiar.

Some cases don't end with a verdict.

They begin there.